Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Blood (2022) 140 (Supplement 1): 1836–1838.

https://doi.org/10.1182/blood-2022-156309

Published: 2022

Journal Articles

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

Carsten Müller-Tidow, MD, Petra Tschanter, MD, Utz Krug, MD, Stefanie Goellner, PhD, Christoph Röllig, MD, Christian Thiede, MD, Anja Koschmieder, Martin Dugas, PhD, Joachim Gerss, PhD, Trude Butterfaß-Bahloul, Ruth Wagner, Stefan W. Krause, MD, Ulrich Kaiser, Volker Kunzmann, MD, Björn Steffen, MD, Richard Noppeney, MD, Wolfgang Herr, MD, Claudia D Baldus, Norbert Schmitz, MD, Katharina Götze, Albrecht Reichle, Martin Kaufmann, MD, Andreas Neubauer, MD, Kerstin Schäfer-Eckart, MD, Mathias Hänel, MD, Rudolf Peceny, MD, Haack Bea, Lilly Meredith, Norbert Frickhofen, MD, Michael G Kiehl, MD, Aristoteles A.N. Giagounidis, MD PhD, Martin Görner, Roland Repp, MD, Ralph Naumann, MD, Hartmut Link, MDPhD, Alexander Kiani, MD, Steffen Koschmieder, MD, Tim H. Brümmendorf, MD, Hubert Serve, MD, Gerhard Ehninger, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 946.

https://doi.org/10.1182/blood.V124.21.946.946

Published: 2014

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype

Blood (2011) 118 (23): 6153–6163.

https://doi.org/10.1182/blood-2011-07-365320

Published: 2011

Includes: Supplemental data

Journal Articles

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Blood (2009) 113 (17): 3903–3910.

https://doi.org/10.1182/blood-2008-07-162842

Published: 2009

Journal Articles

Adoptive Donor T-Cell Infusions Are Necessary and Efficient To Induce Lasting Molecular Remissions after Highly Purified CD34+ Sibling Donor Transplants for First Chronic Phase Chronic Myeloid Leukemia - Final Report and Long-Term Follow-Up of a Phase II Study.

Ahmet Elmaagacli, MD, Rudolf Peceny, M.D., Michael Koldehoff, M.D., Hellmut Ottinger, M.D., Rudolf Trenschel, M.D., Nina K. Steckel, M.D., Dietrich W. Beelen, M.D.

Blood (2006) 108 (11): 3017.

https://doi.org/10.1182/blood.V108.11.3017.3017

Published: 2006

Journal Articles

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias

Dietrich W. Beelen, Hellmut D. Ottinger, Stanislav Ferencik, Ahmet H. Elmaagacli, Rudolf Peceny, Rudolf Trenschel, Hans Grosse-Wilde

Blood (2005) 105 (6): 2594–2600.

https://doi.org/10.1182/blood-2004-04-1441

Published: 2005

Journal Articles

Myeloablative Treosulfan as Preparative Regimen for Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Experience.

Rudolf Trenschel, MD, Markus Ditschkowski, MD, Ahmet Elmaagacli, MD, Nina K. Steckel, MD, Michal Hlinka, MD, Rudolf Peceny, MD, Helmut Ottinger, MD, Michael Koldehoff, MD, Harry Biersack, MD, Michael Flasshove, MD, Dietrich W. Beelen, MD

Blood (2004) 104 (11): 3343.

https://doi.org/10.1182/blood.V104.11.3343.3343

Published: 2004

Journal Articles

Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors

Hellmut D. Ottinger, Stanislav Ferencik, Dietrich W. Beelen, Monika Lindemann, Rudolf Peceny, Ahmed H. Elmaagacli, Johannes Hüsing, Hans Grosse-Wilde

Blood (2003) 102 (3): 1131–1137.

https://doi.org/10.1182/blood-2002-09-2866

Published: 2003

Journal Articles

Outcome of transplantation of highly purified peripheral blood CD34 + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia

Ahmet H. Elmaagacli, Rudolf Peceny, Nina Steckel, Rudolf Trenschel, Hellmut Ottinger, Hans Grosse-Wilde, Ulrich W. Schaefer, Dietrich W. Beelen

Blood (2003) 101 (2): 446–453.

https://doi.org/10.1182/blood-2002-05-1615

Published: 2003

Journal Articles

Improved disease-free–survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia

Ahmet H. Elmaagacli, Semiha Basoglu, Rudolf Peceny, Rudolf Trenschel, Hellmut Ottinger, Andre Lollert, Volker Runde, Hans Grosse-Wilde, Dietrich W. Beelen, Ulrich W. Schaefer

Blood (2002) 99 (4): 1130–1135.

https://doi.org/10.1182/blood.V99.4.1130.h8001130_1130_1135

Published: 2002

NARROW

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Azacitidine Followed By Intensive Induction/Consolidation Chemotherapy in Older Patients with Acute Myeloid Leukemia (AML): Results from the Randomized AML-AZA Trial of the Study Alliance Leukemias (SAL)

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Adoptive Donor T-Cell Infusions Are Necessary and Efficient To Induce Lasting Molecular Remissions after Highly Purified CD34+ Sibling Donor Transplants for First Chronic Phase Chronic Myeloid Leukemia - Final Report and Long-Term Follow-Up of a Phase II Study.

Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias

Myeloablative Treosulfan as Preparative Regimen for Allogeneic Haematopoietic Stem Cell Transplantation: A Single-Centre Experience.

Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors

Outcome of transplantation of highly purified peripheral blood CD34 + cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia

Improved disease-free–survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only